icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
" In view of :
- the efficacy and safety data versus placebo,
- the absence of direct comparative data versus other anti-ANF agents, particularly infliximab,
the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies."
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
ZHZdw4FAswKvvzSg